Exploring Ehlers-Danlos Syndrome, Arthrochalasis Type: Genetic Testing as a Guiding Light
Medically reviewed by Brandon Colby, MD, last reviewed
Update coming in December 2026: The criteria used to diagnose Ehlers-Danlos syndrome (EDS) and hypermobility spectrum disorders (HSD) are being updated for the first time since 2017. If you already have a diagnosis, you do not need to be reevaluated just because the classification is changing. Read our EDS diagnostic criteria update to see what changes for you.
Understanding Ehlers-Danlos Syndrome, Arthrochalasis Type
Ehlers-Danlos Syndrome (EDS) is a group of connective tissue disorders with a variety of symptoms, primarily affecting the skin, joints, and blood vessel walls. Among its many types, the arthrochalasis type (EDS-AT) is particularly rare and severe. Characterized by joint hypermobility, skin that is overly elastic, and fragile tissues, EDS-AT can significantly impact a person's quality of life.
The arthrochalasis type is unique because it involves congenital hip dislocation and severe joint hypermobility, often leading to recurrent dislocations. This type of EDS is associated with mutations in the COL1A1 or COL1A2 genes, which affect collagen production. Given its genetic basis, understanding and diagnosing EDS-AT can be greatly enhanced by genetic testing.
Genetic Testing: A Window into EDS-AT
Diagnosis and Confirmation
Genetic testing serves as a crucial tool for diagnosing EDS-AT. Since this condition involves specific genetic mutations, testing for these mutations can confirm a diagnosis. This is particularly important in distinguishing EDS-AT from other types of Ehlers-Danlos Syndrome and similar connective tissue disorders. A confirmed genetic diagnosis can guide healthcare providers in tailoring management plans for affected individuals.
Identifying Family Risk
Given the hereditary nature of Ehlers-Danlos Syndrome, genetic testing can identify family members who may be at risk. By understanding the genetic mutations involved, family members can undergo testing to determine their risk of developing the condition or passing it on to future generations. This knowledge can be empowering, allowing families to make informed decisions about their health and family planning.
Personalized Treatment Plans
Genetic testing not only aids in diagnosis but also in crafting personalized treatment plans. By understanding the specific genetic mutations involved, healthcare providers can predict potential complications and tailor interventions accordingly. This personalized approach can improve patient outcomes and enhance quality of life by addressing the unique needs of each individual with EDS-AT.
Research and Future Therapies
Genetic testing plays a pivotal role in advancing research on EDS-AT. By identifying and studying the genetic mutations associated with this condition, researchers can develop targeted therapies. These therapies have the potential to address the root causes of EDS-AT, offering hope for more effective treatments in the future. Genetic testing is thus a cornerstone of ongoing research efforts to better understand and eventually cure this rare disorder.
What Is the December 2026 EDS Diagnostic Criteria Update?
The Ehlers-Danlos Society is expected to publish an updated classification framework for the Ehlers-Danlos syndromes and hypermobility spectrum disorders in December 2026, the first major update since 2017. If you already have a diagnosis, you do not need to be reevaluated solely because the classification is changing. See how Sequencing is preparing in our guide to the EDS classification update.
Research on Hypermobile EDS and Dysautonomia
Sequencing and the Norris Lab at the Medical University of South Carolina have opened a research study on hypermobile EDS (hEDS) and dysautonomia. If you already have whole genome sequencing with Sequencing, you can choose whether to take part. Participation is voluntary, data is de-identified, and individual results are not returned. Read why we are launching our patient driven genetic study for hypermobile Ehlers-Danlos syndrome and dysautonomia.
Conclusion: The Promise of Genetic Testing
In the realm of Ehlers-Danlos Syndrome, arthrochalasis type, genetic testing emerges as a powerful ally. It provides clarity in diagnosis, identifies familial risk, enables personalized treatment, and fuels research into future therapies. For those affected by EDS-AT, genetic testing offers a beacon of hope, illuminating the path to better understanding and management of this challenging condition.
As research continues to evolve, the role of genetic testing in managing EDS-AT is likely to expand, offering new possibilities for patients and their families. Embracing this technology can lead to improved outcomes and a brighter future for those living with Ehlers-Danlos Syndrome, arthrochalasis type.